4-({9-シクロペンチル-7,7-ジフルオロ-5-メチル-6-オキソ-5H,6H,7H,8H,9H-ピリミド[4,5-b][1,4]ジアゼピン-2-イル}アミノ)-2-フルオロ-5-メトキシ-N-(1-メチルピペリジン-4-イル)ベンズアミド

PLK1 Inhibitor TAK-960 is an orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressed tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis.